​Cancer drug startup raises $3.7 million in Dallas venture capital

Dallas biotech company Lantern Pharma has closed on a $3.7 million venture capital raise, which was led by a pair of local investment firms. The series A equity financing was headed up by Bios Partners and Green Park and Gold Ventures – both based in the Dallas-Fort Worth area. The exact terms of the deal were not immediately disclosed. GPG led Lantern’s $960,000 capital raise in 2015 shortly after it graduated from startup accelerator Health Wildcatters. Lantern acquires drugs in the later…...